The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
{{output}}
Development of novel antibodies to combat the novel SARS-CoV-2 virus is ongoing. Importantly, particular subgroups are more prone to severe disease, namely patients with poor immune responses. This includes cancer patients with solid and haematological disease... ...
